Fosun RZ Capital

Chairman Pan Zhang and Managing Partner Xiaoxin Qiu oversee the investment team from the firm’s Beijing headquarters. The two principals set strategy across the seven global offices, drawing on the parent company’s industrial presence in health, consumer, finance, and smart manufacturing. The firm presents itself as a unified platform rather than a distributed partnership, meaning major allocation calls trace back to the Beijing leadership.

Deal origination leans heavily on Fosun International’s operating subsidiaries across Asia, Europe, and the Americas. The parent operates in 35 countries through insurance, pharmaceutical, consumer, and steel businesses, giving the venture team early visibility into startups that can slot into those supply chains or distribution networks. Additionally, the firm maintains dedicated teams in Silicon Valley and Tel Aviv to capture innovation at its source before companies look to Asian markets.

The firm’s core activity is direct equity investment into private companies, from seed rounds through late-stage venture. It is not disclosed whether the platform allocates to external China- or US-focused VC funds as a limited partner. Its public materials emphasize principal investing — writing equity checks from its own RMB- and USD-denominated funds — rather than fund-of-funds activity.

The firm covers the full venture lifecycle: seed, start-up, early-stage, expansion, late-stage, and growth equity. In practice, its most visible deals cluster around Series A through late-stage, where a company is ready to scale into Chinese or Southeast Asian markets. Seed investments are less frequently disclosed but are part of the stated strategy, especially in frontier technology and AI.

Fosun RZ Capital is a wholly owned subsidiary of Fosun International Limited (0656.HK), a Fortune Global 500 company. The parent provides permanent capital and strategic deal flow, but it also gives the venture arm an alternative exit path: portfolio companies can be sold into Fosun’s own insurance, pharma, or consumer divisions instead of going through a traditional IPO or third-party trade sale. The Quantium Pai IPO in 2025, where Fosun Wealth acted as joint bookrunner, shows the parent actively participates in liquidity events.